Propanc Biopharma, Inc. - 10-Q Summary (Q1 2025 / Period Ended Sept 30, 2024)
Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended September 30, 2024 (Fiscal Q1 2025)
Business Overview: A development-stage biopharmaceutical company focused on cancer treatments, specifically its lead product candidate PRP (a pro-enzyme formulation). The company has no commercial revenue and relies on debt and equity financing. Operations are based in Australia with R&D in the EU.
Key Financial Metrics
| Metric | Q1 2025 (Sept 30, 2024) | Q1 2024 (Sept 30, 2023) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(354,310) | $(350,866) |
| Cash and Cash Equivalents | $9,268 | $6,625 |
| Total Assets | $63,644 | $72,365 |
| Total Liabilities | $4,171,729 | $3,851,424 |
| Stockholders' Deficit | $(4,108,085) | $(3,779,059) |
| Working Capital Deficit | $(4,079,710) | $(3,767,341) |
| Net Cash Used in Operating Activities | $(235,515) | $(333,457) |
| Net Cash Provided by Financing Activities | $215,699 | $350,347 |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by approximately $126,000 to $290,790, driven primarily by a $173,000 reduction in administration expenses (lower consulting and legal fees), partially offset by a $45,000 increase in R&D expenses.
- Interest and Derivative Costs: Interest expense decreased by $92,000 due to lower amortization of debt discounts and accretion of put premiums. Derivative expense decreased by $50,000.
- Debt Position: Current liabilities increased by approximately $309,000. Notable increases include "Loans payable - related parties" (up $155,699) and "Employee benefit liability" (up $38,531). Convertible notes decreased slightly due to conversions.
- Equity Issuance: The company issued 194,219,529 shares of common stock for the conversion of debt and 15,000,000 shares for services during the quarter.
Outlook, Risks, and Contingencies
- Going Concern: Management states that conditions raise substantial doubt about the company's ability to continue as a going concern for 12 months. The company has a significant accumulated deficit ($67M) and negative working capital. Continued operations depend on securing additional financing.
- Debt Defaults: The company is currently in default on several debt instruments, including a $65,280 loan from Crown Bridge and convertible notes totaling $83,000 principal. Management is negotiating extensions with lenders.
- Reverse Stock Split: The company received shareholder approval for a 1:60,000 reverse stock split and is awaiting FINRA approval. An S-1 registration statement was filed in October 2024 for an underwritten offering.
- Internal Controls: The company identified material weaknesses in internal controls, including lack of written documentation, insufficient segregation of duties, and lack of an audit committee.
- Patent Status: Received allowance for a "proenzyme composition" patent in Canada in August 2024. The company holds 84 granted/allowed patents globally.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $9,268 cash balance against the $4.1M in current liabilities and ongoing burn rate.
- Debt Restructuring: Confirm the status of negotiations regarding the defaulted notes and loans to avoid acceleration of debt.
- Reverse Split Approval: Monitor FINRA approval status for the 1:60,000 reverse stock split, which is a prerequisite for the planned Nasdaq uplisting.
- Capital Raise Progress: Track the status of the S-1 registration and the ability to close the proposed underwritten offering.
- Related Party Transactions: Review the terms of the $227,328 in related party loans and the $140,890 in accrued rent payable to a related party.